Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Randomized, Placebo-controlled, Double-blind, Parallel-group Phase 2a Exploratory Study With Placebo run-in to Investigate PK/PD Effects, Safety, Tolerability and Pharmacokinetics of REM0046127 Oral Suspension Compared With Placebo in Subjects With Mild to Moderate Alzheimer's Disease

Authors not listed

reMYND · 2022

Abstract

The purpose of this study is to measure effects on CSF biomarkers, EEG and safety with REM0046127 oral suspension compared with placebo in subjects with mild to moderate Alzheimer disease. * The study duration will be up to 2 months for each treated subject * Each subject will start with a 14-day placebo run-in period, followed by a 28-day treatment period and 7-day follow-up period * Visit frequency: every week * Number of Subjects: at least 30 subjects with an upper limit of 60 subjects. * Study Arms and Duration: All subjects will be randomized (1:1:1 allocation) to one ofthree different starting levels after the 14-day run-in period: * REM0046127 high dose: 1400mg (700mg bid) oral suspension per day for 28 days * REM0046127 low dose: 350mg (175mg bid) oral suspension per day for 28 days * Placebo: placebo oral suspension bid for 28 days

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-08 MST

Cite this

APA
Anonymous. (2022). A Randomized, Placebo-controlled, Double-blind, Parallel-group Phase 2a Exploratory Study With Placebo run-in to Investigate PK/PD Effects, Safety, Tolerability and Pharmacokinetics of REM0046127 Oral Suspension Compared With Placebo in Subjects With Mild to Moderate Alzheimer's Disease. <em>reMYND</em>. https://clinicaltrials.gov/study/NCT05478031
Vancouver
Anonymous. A Randomized, Placebo-controlled, Double-blind, Parallel-group Phase 2a Exploratory Study With Placebo run-in to Investigate PK/PD Effects, Safety, Tolerability and Pharmacokinetics of REM0046127 Oral Suspension Compared With Placebo in Subjects With Mild to Moderate Alzheimer's Disease. reMYND. 2022.
BibTeX
@misc{anon2022ARando, title = {A Randomized, Placebo-controlled, Double-blind, Parallel-group Phase 2a Exploratory Study With Placebo run-in to Investigate PK/PD Effects, Safety, Tolerability and Pharmacokinetics of REM0046127 Oral Suspension Compared With Placebo in Subjects With Mild to Moderate Alzheimer's Disease}, author = {Anonymous}, journal = {reMYND}, year = {2022}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings